Stephens Consulting’s Integra LifeSciences IART Stock Holding History

Stephens Consulting’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20	Closed	-$440	–	1557
2025 Q1	$440	Buy	+20	New	+$470	﹤0.01%	958

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stephens Consulting's IART Position: Q2 2025 in Review

Stephens Consulting sold out of Integra LifeSciences (IART) in Q2 2025, closing a stake of 20 shares — an estimated $440 sold.

Stephens Consulting first reported a position in IART in Q1 2025 and held it in 1 quarter. The position peaked at $440 in Q1 2025. 208 funds tracked by Wall St. Rank hold IART as of Q2 2025.

Stephens Consulting reported no remaining Integra LifeSciences position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 20 Integra LifeSciences shares in Q2 2025, an estimated $440.
Stephens Consulting first reported a position in Integra LifeSciences in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Integra LifeSciences position peaked at $440 in Q1 2025.
208 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.